Intellia Therapeutics vs Trinity Biotech
NTLA and TRIB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NTLA and TRIB compare
Intellia Therapeutics grew revenue faster over the last twelve months (−8.1% versus −28.9% for Trinity Biotech).
Trinity Biotech keeps more of each dollar of sales as profit, with a net margin of −85.4% compared with −806% at Intellia Therapeutics.
Intellia Therapeutics scores higher on the StockData Score (3 against 1 for Trinity Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NTLA | TRIB |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | – |
| Share price | $9.70 | $6.10 |
| Change, 1 year | 2.2% | −77.4% |
| Change, 5 years | −92.5% | −97.9% |
| Beta (5Y) | 2.08 | 1.44 |
| Employees | 377 | 287 |
| StockData Score | ||
| Total score | 3 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 25.7× | – |
| P/B | 2.2× | – |
| FCF yield | −26.3% | – |
| Fair value | $7.77 | – |
| Margin of safety | −24.9% | – |
| Growth | ||
| Revenue growth (TTM) | −8.1% (better) | −28.9% |
| Revenue growth, 5Y average | 3.1% (better) | −15.6% |
| Profitability | ||
| Gross margin | – | 38.6% |
| Operating margin | −821% | −36.1% (better) |
| Net margin | −806% | −85.4% (better) |
| FCF margin | −677% | −13.7% (better) |
| Return on equity | −62.6% | – |
| Return on invested capital | −152% | – |
| Financial health | ||
| Debt / equity | 0.12 | – |
| Interest coverage | – | −0.7× |
| Current ratio | 6.31 (better) | 0.25 |
| Altman Z-score | −2.68 | – |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 103% | 0.01% |
| Held by insiders | 2.0% | 51.7% |
| Insider net buying, 12 months | −$869K | – |
| Short interest, % of float | 32.3% | – |
Go deeper
- NTLA stock overview
- NTLA income statement
- NTLA valuation and score
- TRIB stock overview
- TRIB income statement
- TRIB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.